Alvotech To Develop Biosimilar Assets With US$300m Financing Deal
Alvotech will further develop its biosimilar assets through a US$300 million financing deal that will also enable the firm to “fuel continued growth” and be used for refinancing existing debt.
You may also be interested in...
Icelandic biosimilars specialist Alvotech has eased some of its liability to bondholders following a debt-to-equity conversion, at the same time as it improved terms and extended its maturity.
In a move to take its pipeline of biosimilar monoclonal antibodies global, Alvotech has struck a deal with Abdi Ibrahim that will give it localization advantages in Turkey.
Mark Levick, Sandoz’ head of development for biopharmaceuticals, has been chosen to become CEO of Alvotech from August.